Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23365798 | 1.00 | TLR2 (0.52) | TLR2NOD1SIRT5EPHX2ALB | |
| SCHEMBL21172243 | 0.89 | NOD1 (0.58) | NOD1EPHX2GLP1R | |
| SCHEMBL27436076 | 0.89 | NOD1 (0.58) | NOD1EPHX2GLP1R | |
| SCHEMBL23365799 | 0.89 | NOD1 (0.58) | NOD1EPHX2GLP1R | |
| SCHEMBL20414814 | 0.89 | NOD1 (0.58) | NOD1EPHX2GLP1R | |
| SCHEMBL20341058 | 0.88 | SIRT5 (0.63) | TLR2NOD1SIRT5EPHX2ALB | |
| SCHEMBL10027319 | 0.88 | MEN1 (0.52) | TLR2NOD1SIRT5EPHX2ALB | |
| SCHEMBL27436171 | 0.85 | NMT1 (0.56) | TLR2NOD1ROCK2GLP1R | |
| SCHEMBL15084766 | 0.85 | NOD1 (0.63) | TLR2NOD1EPHX2ALBGLP1R | |
| SCHEMBL24592963 | 0.85 | SIRT5 (0.47) | TLR2NOD1SIRT5ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | TLR2 3926/4885NOD1 2918/4885SIRT5 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.